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Sample: 239 patients from European Organization for Research and Treatment of Cancer (EORTC) treated according to the current gold 
standard (debulking surgery, radiotherapy plus concomitant and adjuvant temozolomide chemotherapy). We used recursive partitioning 
analysis to create a prognostic classification tree for GBM patients (left figure). PFS (progression-free survival) and OS (overall survival) are 
expressed in days.  
Patients in Class 1, with good clinical performance (0 or 1) and MGMT promoter methylation, have a mean survival of nearly 3 years. 
Patients in Class 5, with low clinical performance and aged over 57.5 years, have a mean survival of 7 months. Survival difference between 
the groups are illustrated on Kaplan-Meier curves (right figure). This method of classification was then applied on two other patients samples 
from Liege University Hospital and TCGA (The Cancer Genome Atlas) and returned comparable results, with very similar age cut-offs.  
Glioblastoma (GBM) still carries a poor prognosis with an average survival of 12 to 15 months. However, survival is variable, ranging from a 
few months to several years, and difficult to predict. Prognostic classification trees exist, based on known clinical factors. These, however, 
were obtained with data collected beginning >30 years ago, when GBM treatment was heterogeneous. Applicability of these classifications 
to the current situation with standard treatments is thus limited. In addition, GBM is a biologically heterogeneous tumour and clinically similar 
patients may have fundamentally different survival outcome.  
First, we will update the clinical stratification of glioblastoma patients, producing a prognostic model in a homogeneous population treated 
according to current standards of care. This will provide clinically more homogeneous prognostic patient groups. 
Second, based on this clinical analysis, biological tumour markers will be associated with survival differences within these prognostic groups. 
1.  Further clinical study data is under request at the EORTC in order to increase patient numbers and significance of the obtained 
prognostic groups. 
2.  Since there still are short and long survivors in each prognostic group, genetic factors influencing survival will be assessed within these 
prognostic groups. The ultimate clinical goal is to refine prognostic predictions for individual patients to guide treatment strategies. 
Thus, prognostic signatures will be established, with the help of bioinformatic techniques, on the TCGA database. Existing molecular 
classifications (Verhaak, 2010) will be applied and new signatures defined within in the clinically homogenous groups (collaboration 
with Norlux Neuro-Oncology Laboratory and Genomics Research Unit, Luxembourg Institute of Health). 
3.  Prospective medical file data assembly and tissue collection are well under way in order to better anticipate tumour progression using 
these biological signatures. 
In a first step, glioblastoma patients were stratified into prognostic groups with distinct survival. Patients with good clinical performance, a 
methylated MGMT promoter and younger age on average survive longer. These results confirm known clinical prognostic factors and 
update regression tree classification to populations treated according to the current treatment standard (Stupp protocol). 
They also illustrate the importance of stratification in clinical research, which reduces potential misinterpretation of the treatment efficacy by 
significantly reducing confounding factors. 
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